These results indicate that NGM-SZ21 is capable of preventing anti-HPA-1a-mediated platelet destruction in vivo even when maternal anti-HPA-1a alloantibodies are already present in the fetal circulation.
No mouse model for fetomaternal incompatibility in human platelet alloantigens currently exists.